Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Veritone Inc (VERI) vs Viatris Inc (VTRS) Price & Performance

Veritone IncTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Veritone Inc vs Viatris Inc — how do they compare? Veritone Inc trades at $1.13 (market cap $97.60M), while Viatris Inc trades at $17.58 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 202.8× Veritone Inc's market cap, and Viatris Inc pays a 2.83% dividend while Veritone Inc pays none. Which is the better fit depends on your goals.

VERIVTRS
Market Cap
$97.60M$19.79B
Sector
TechnologyHealth
52-Week High
$8.39$17.39
52-Week Low
$1.02$8.74
Enterprise Value
$129.63M$32.00B
Dividend Yield
2.83%

Returns comparison

Trailing returns across standard periods

About Veritone Inc

Veritone is a leading provider of enterprise AI software and solutions, centered on its proprietary AI operating system, aiWARE™. The platform orchestrates a vast ecosystem of machine learning models to transform unstructured data—such as audio, video, and text—into actionable intelligence. Serving the media, entertainment, and public sectors, Veritone is a critical infrastructure partner for organizations looking to monetize data archives and operationalize AI at scale.

Read more on VERI

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS